Down 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM)
The heavy selling pressure might have exhausted for Tandem Diabetes Care (TNDM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +
Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.
Tandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue?
Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock?
Should Tandem Diabetes Stock Stay in Your Portfolio Now?
Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.
TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up
Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.
Tandem Diabetes Care, Inc. (TNDM) Q1 2025 Earnings Conference Call Transcript
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Susan Morrison - EVP & Chief Administrative Officer John Sheridan - President & CEO Leigh Vosseller - EVP & CFO Conference Call Participants Matt Miksic - Barclays Mat Blackman - Stifel Steve Lichtman - Oppenheimer & Company Matthew O'Brien - Piper Sandler David Roman - Goldman Sachs Matthew Taylor - Jeffries Chris Pasquale - Nephron Research Anthony Petrone - Mizuho Financial Groups Joshua Jennings - TD Cowen Issie Kirby - Redburn Atlantic Nathan Trebek - Wells Fargo Mike Kratky - Leerink Partners Jayson Bedford - Raymond James & Associates William Plovanic - Canaccord Genuity Michael Polark - Wolfe Research Danielle Antalffy - UBS Stephanie Piazzolla - Bank of America Securities Shagun Singh - RBC Operator Good day, and thank you for standing by. Welcome to the Tandem Diabetes Care First Quarter 2025 Earnings Conference Call.
Tandem Diabetes Care (TNDM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.63 per share a year ago.
Reasons to Hold TNDM Stock in Your Portfolio for Now
A robust diabetes market and international expansion raise investors' optimism for Tandem Diabetes.
Tandem Diabetes Care (TNDM) Moves 7.6% Higher: Will This Strength Last?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology
Tandem Diabetes launches Control-IQ+ technology commercially in the United States. Control-IQ+ is compatible with t:slim X2 insulin pump and Tandem Mobi System.
Reasons to Hold TNDM Stock in Your Portfolio for Now
A robust product innovation and several strategic developments raise investors' optimism for Tandem Diabetes.
